Looking for more mental health CME?
Enroll in Mental Health Bootcamp, an on-demand curriculum with over 30 courses, a library of downloadable resources, and Q&A with faculty.
Learn More
This activity is part of the Frankly Speaking with Dr. Frank Domino podcast series.
Podcast
Selecting Medication for Depression: Do Genomics Matter? - Frankly Speaking EP 304Guest: Alan M. Ehrlich, MD, FAAFP
Music Credit: Richard Onorato
Pharmacogenomic testing has been suggested as a way to personalize medicine, particularly where the metabolism of medications can vary significantly. Unfortunately, despite increasing use of this testing, there has been little evidence showing a benefit in clinical outcomes. Listen to this podcast to explore the data on clinical outcomes for pharmacogenetic testing and how to best select medication for patients with depression.
Episode References and Resources:
- Oslin DW, Lynch KG, Shih MC, et al. Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial. JAMA. 2022;328(2):151-161.
Begin
Already listened on another platform?
CME/CE Information
0 Credits - Not for CME/CE Credit
Release Date: 11/28/2022
Expiration Date: 11/28/2024
Learning Objectives
- Discuss whether pharmacogenomics can be used to improve medication selection
- Summarize the available treatment options for depression
Faculty
Frank J. Domino, MD
Professor, Family Medicine and Community Health,
University of Massachusetts Medical School, Worcester, MA
Alan M. Ehrlich, MD, FAAFP
Associate Professor of Family Medicine and Community Health, University of Massachusetts Medical School,
Executive Editor, DynaMed
Disclosures
The following financial relationships have been disclosed by faculty.
Frank J. Domino, MD
Has disclosed no relevant financial relationships.
Alan Ehrlich, MD, FAAFP
Has disclosed no relevant financial relationships.
Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.
Supporters and Partners
Supported by
Not Applicable
Education Partner
Not Applicable
Fine Print
The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.
Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.
Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. Pri-Med Institute is the accredited provider for this activity.
Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.
Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.
Questions?
If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.